arachidonic acidWhat was measured
Measured, with no finding
473 endpoints
Show what was measuredHide what was measured
EGC-3'-O-glucuronide formation catalytic efficiency (Vmax/Km) across tissues
unclear
The V(max)/K(m) for (-)-EGC-3'-O-glucuronide followed the following order: mouse liver > human liver > rat liver > rat and mouse small intestine.
PMID 12642472 · one of two readings recorded this
EGCG-4"-O-glucuronide formation catalytic efficiency (Vmax/Km) across tissues
unclear
The catalytic efficiency (V(max)/K(m)) for (-)-EGCG-4"-O-glucuronide formation followed the order: mouse intestine > mouse liver > human liver > rat liver >> rat small intestine.
PMID 12642472 · one of two readings recorded this
Release of arachidonic acid from HT-29 cells
decreases
Some of these catechin glucuronides retained the activities of their parent compounds in radical scavenging and in inhibiting the release of arachidonic acid from HT-29 human colon cancer cells.
PMID 12642472 · one of two readings recorded this
ARA level versus breast-fed
no effect
In contrast, ARA was not significantly lower compared with B in any group in any tissue but was significantly elevated in liver and brain.
PMID 12736388 · one of two readings recorded this
DHA concentration, all tissues
increases
The B and P+ groups had significantly higher DHA concentration in all tissues than T- and P-.
PMID 12736388 · one of two readings recorded this
DHA content, brain
decreases
The P- group showed dramatically lower DHA content of 35%, 27%, 66%, and 75% in the brain, retina, liver, and plasma, respectively, compared with B.
PMID 12736388 · one of two readings recorded this
DHA content, liver
decreases
The P- group showed dramatically lower DHA content of 35%, 27%, 66%, and 75% in the brain, retina, liver, and plasma, respectively, compared with B.
PMID 12736388 · one of two readings recorded this
DHA content, plasma
decreases
The P- group showed dramatically lower DHA content of 35%, 27%, 66%, and 75% in the brain, retina, liver, and plasma, respectively, compared with B.
PMID 12736388 · one of two readings recorded this
DHA content, retina
decreases
The P- group showed dramatically lower DHA content of 35%, 27%, 66%, and 75% in the brain, retina, liver, and plasma, respectively, compared with B.
PMID 12736388 · one of two readings recorded this
RBC/plasma ARA correlation with tissue ARA
no effect
RBC and plasma DHA were correlated with DHA in tissues; RBC/plasma ARA were uncorrelated with tissue ARA.
PMID 12736388 · one of two readings recorded this
Brain linoleic acid-derived ARA accretion
no effect
Brain linoleic acid-derived ARA accretion was significantly greater in the unsupplemented term group but not in the preterm groups compared with the breast-fed group.
PMID 14523049 · one of two readings recorded this
Brain linoleic acid-derived ARA accretion
increases
Brain linoleic acid-derived ARA accretion was significantly greater in the unsupplemented term group but not in the preterm groups compared with the breast-fed group.
PMID 14523049 · one of two readings recorded this
Brain linolenic acid-derived DHA accretion
increases
Brain accretion of linolenic acid-derived DHA was approximately 3-fold greater for the formula groups than for the breast-fed group
PMID 14523049 · one of two readings recorded this
DHA level and neurite length per neuron
decreases
Furthermore, hippocampal cultures obtained from n-3 fatty acid deficient animals contained a lower DHA level and a neuronal population with shorter neurite length per neuron in comparison to those obtained from animals with adequate n-3 fatty acids.
PMID 15287904 · one of two readings recorded this
Neurite growth
no effect
However, supplementation with arachidonic, oleic or docosapentaenoic acid did not have any effect, indicating specificity of the DHA action on neurite growth.
PMID 15287904 · one of two readings recorded this
Neurite growth
no effect
However, supplementation with arachidonic, oleic or docosapentaenoic acid did not have any effect, indicating specificity of the DHA action on neurite growth.
PMID 15287904 · one of two readings recorded this
Neurite growth
no effect
However, supplementation with arachidonic, oleic or docosapentaenoic acid did not have any effect, indicating specificity of the DHA action on neurite growth.
PMID 15287904 · one of two readings recorded this
Neurite length in deficient cultures
increases
DHA supplementation to the deficient group recovered the neurite length to the level similar to n-3 fatty acid adequate cultures.
PMID 15287904 · one of two readings recorded this
neurite length per neuron and branch number in rat embryonic hippocampal primary cultures
no effect
Not recorded as a finding: this platform holds no node for the endpoint
However, supplementation with arachidonic, oleic or docosapentaenoic acid did not have any effect, indicating specificity of the DHA action on neurite growth.
PMID 15287904 · one of two readings recorded this
neurite length per neuron and number of branches in rat embryonic hippocampal primary cultures
no effect, supplementation with arachidonic acid did not have any effect on neurite growth
Not recorded as a finding: this platform holds no node for the endpoint
However, supplementation with arachidonic, oleic or docosapentaenoic acid did not have any effect, indicating specificity of the DHA action on neurite growth.
PMID 15287904 · one of two readings recorded this
Neurite length per neuron and number of branches
increases
We found that DHA supplementation in culture increased the population of neurons with longer neurite length per neuron and with higher number of branches.
PMID 15287904 · one of two readings recorded this
birth weight
Birth weight (g)c | 875 ± 65A | 821 ± 119A | 894 ± 96A | 632 ± 61B | 608 ± 71B
PMID 15975147 · one of two readings recorded this
22:5n-6 (Osbond acid) concentration, Corpus Callosum
modulates
Corpus Callosum | 1.16 ± 0.22 | 1.79 ± 0.26 | 1.43 ± 0.27 | 1.41 ± 0.22 | 1.94 ± 0.33 | T+,P->B; T->T+; T+>P+; P->T-,P+
PMID 15975147 · one of two readings recorded this
22:5n-6 (Osbond acid) concentration, Hippocampus
modulates
Hippocampus | 1.86 ± 0.30 | 2.27 ± 0.40 | 2.28 ± 0.41 | 1.88 ± 0.16 | 2.33 ± 0.14 | T+,T-,P->B; T+,T-,P->P+
PMID 15975147 · one of two readings recorded this
22:5n-6 (Osbond acid) concentration, Occipital
modulates
Occipital | 1.97 ± 0.23 | 2.26 ± 0.32 | 2.47 ± 0.40 | 1.85 ± 0.23 | 2.39 ± 0.16 | T-,P->B; T+,T-,P->P+
PMID 15975147 · one of two readings recorded this
ARA concentration, breastfed versus P- in affected regions
decreases
Remarkably, the B group is of lower ARA concentration than the P- group in every case, and this is significant in 7 of 8 regions
PMID 15975147 · one of two readings recorded this
ARA concentration, Corpus Collosum
modulates
Corpus Collosum | 9.9 ± 0.6 | 11.2 ± 0.5 | 10.2 ± 0.7 | 11.3 ± 0.5 | 11.4 ± 0.9 | [T+,P+,P->B; T+,P+,P->T-]
PMID 15975147 · one of two readings recorded this
ARA concentration, Hypothalamus
modulates
Hypothalamus | 11.7 ± 0.7 | 12.2 ± 0.6 | 11.4 ± 0.4 | 12.6 ± 0.7 | 12.9 ± 0.5 | [T+,P+,P->T-; P+,P->B]
PMID 15975147 · one of two readings recorded this
ARA concentration, Inferior Colliculus
modulates
Inferior Colliculus | 9.3 ± 0.5 | 10.5 ± 1.0 | 9.3 ± 0.7 | 10.3 ± 0.5 | 10.3 ± 0.4 | [T+,P+,P->B,T-]
PMID 15975147 · one of two readings recorded this
ARA concentration, Lateral Geniculate
modulates
Lateral Geniculate | 9.5 ± 1.1 | 10.6 ± 0.6 | 9.9 ± 0.4 | 10.7 ± 0.5 | 10.5 ± 0.4 | [T+,P+,P->B; P+>T-]
PMID 15975147 · one of two readings recorded this
ARA concentration, Occipital
modulates
Occipital | 13.2 ± 0.8 | 13.3 ± 0.7 | 13.6 ± 0.8 | 14.0 ± 0.5 | 14.3 ± 0.6 | [P->B,T+]
PMID 15975147 · one of two readings recorded this
ARA concentration, Optic Tract
modulates
Optic Tract | 6.8 ± 0.3 | 6.9 ± 0.4 | 7.2 ± 0.7 | 7.4 ± 0.3 | 7.7 ± 0.4 | [P-,P+>B; P->T+]
PMID 15975147 · one of two readings recorded this
ARA concentration, Superior Colliculus
modulates
Superior Colliculus | 10.1 ± 0.9 | 11.0 ± 0.8 | 10.6 ± 0.7 | 11.0 ± 0.6 | 11.7 ± 0.6 | [T+,P+,P->B; P->T-]
PMID 15975147 · one of two readings recorded this
ARA concentration, Thalamus DM
modulates
Thalamus DM | 10.0 ± 0.5 | 10.3 ± 0.6 | 9.6 ± 0.8 | 10.8 ± 0.6 | 10.7 ± 0.7 | [T+,P+,P->T-; P+>B]
PMID 15975147 · one of two readings recorded this
body weight at euthanasia
Body weight at euthanasia (g)d | 1152 ± 177 | 1147 ± 113 | 1107 ± 145 | 1071 ± 187 | 1035 ± 220
PMID 15975147 · one of two readings recorded this
brain weight at euthanasia
Brain weight at euthanasia (g)d | 103 ± 4 | 98 ± 6 | 100 ± 11 | 93 ± 8 | 94 ± 9
PMID 15975147 · one of two readings recorded this
DHA concentration, Amygdala
modulates
Amygdala | 12.0 ± 0.6 | 11.4 ± 0.6 | 10.8 ± 0.9 | 11.7 ± 0.5 | 9.4 ± 0.4 | [B>T-,P-; T+,T-,P+>P-; P+>T-]
PMID 15975147 · one of two readings recorded this
DHA concentration, Caudate
modulates
Caudate | 14.3 ± 1.1 | 13.4 ± 0.8 | 13.0 ± 1.1 | 13.5 ± 0.8 | 11.3 ± 0.4 | [B>T-,P-; T+,T-,P+>P-]
PMID 15975147 · one of two readings recorded this
DHA concentration, Cerebellum
modulates
Cerebellum | 12.6 ± 0.9 | 11.2 ± 0.7 | 10.6 ± 0.8 | 11.4 ± 0.2 | 7.7 ± 0.6 | [B>all; T+>P-; T-,P+>P-]
PMID 15975147 · one of two readings recorded this
DHA concentration, Cingulate
modulates
Cingulate | 13.4 ± 0.9 | 11.4 ± 0.7 | 10.7 ± 0.8 | 11.8 ± 0.8 | 9.5 ± 0.9 | [B>all; T+>P-; P+>T-,P-; T->P-]
PMID 15975147 · one of two readings recorded this
DHA concentration, Corona Radiation
modulates
Corona Radiation | 5.5 ± 0.9 | 5.2 ± 0.9 | 4.4 ± 0.4 | 5.7 ± 0.8 | 4.7 ± 0.7 | [B>T-; P+>T-,P-]
PMID 15975147 · one of two readings recorded this
DHA concentration, Corpus Callosum
modulates
Corpus Callosum | 7.0 ± 1.3 | 7.9 ± 0.7 | 6.4 ± 0.9 | 8.2 ± 0.7 | 6.3 ± 0.7 | [T+>T-,P-; P+>B,T-,P-]
PMID 15975147 · one of two readings recorded this
DHA concentration, Frontal
modulates
Frontal | 12.7 ± 0.6 | 11.2 ± 0.8 | 10.6 ± 0.7 | 11.4 ± 0.4 | 8.4 ± 1.0 | [B>all; T+>P+,P-; T->P-; P+>P-]
PMID 15975147 · one of two readings recorded this
DHA concentration, Globus Pallidus
modulates
Globus Pallidus | 15.8 ± 0.5 | 15.4 ± 0.6 | 12.7 ± 2.3 | 16.6 ± 0.3 | 13.4 ± 1.5 | [B>T-,P-; T+>T-,P-; P+>T-,P-]
PMID 15975147 · one of two readings recorded this
DHA concentration, Hippocampus
modulates
Hippocampus | 13.0 ± 0.8 | 11.6 ± 0.5 | 10.6 ± 1.5 | 12.6 ± 0.5 | 9.0 ± 0.5 | [B>T+,T-,P-; T+,T-,P+>P-; P+>T-]
PMID 15975147 · one of two readings recorded this
DHA concentration, Hypothalamus
modulates
Hypothalamus | 12.0 ± 0.4 | 11.3 ± 0.6 | 11.0 ± 0.7 | 12.0 ± 0.8 | 10.6 ± 0.4 | [B>T-,P-; T+>P-; P+>T-,P-]
PMID 15975147 · one of two readings recorded this
DHA concentration, Inferior Colliculus
modulates
Inferior Colliculus | 14.4 ± 1.0 | 12.9 ± 1.4 | 13.4 ± 1.3 | 15.0 ± 0.6 | 13.4 ± 0.4 | [B>T+; P+>T+,T-,P-]
PMID 15975147 · one of two readings recorded this
DHA concentration, Internal Capsule
no effect
Internal Capsule | 6.8 ± 1.0 | 7.0 ± 1.5 | 6.4 ± 0.7 | 7.9 ± 0.9 | 6.3 ± 1.4
PMID 15975147 · one of two readings recorded this
DHA concentration, Lateral Geniculate
modulates
Lateral Geniculate | 11.2 ± 1.6 | 10.6 ± 0.9 | 9.5 ± 0.8 | 11.7 ± 0.7 | 8.8 ± 1.8 | [B>T-,P-; T+>P-; P+>T-,P-]
PMID 15975147 · one of two readings recorded this
DHA concentration, Medial Geniculate
no effect
Medial Geniculate | 12.5 ± 1.3 | 12.8 ± 1.1 | 12.2 ± 0.9 | 12.6 ± 1.3 | 11.7 ± 0.8
PMID 15975147 · one of two readings recorded this
DHA concentration, Occipital
modulates
Occipital | 13.9 ± 1.0 | 11.7 ± 0.9 | 10.7 ± 0.8 | 11.8 ± 0.1 | 8.7 ± 0.6 | [B>all; T+>P+,P-; T->P+,P-; P+>P-]
PMID 15975147 · one of two readings recorded this
DHA concentration, Optic Nerve
modulates
Optic Nerve | 4.5 ± 0.5 | 4.0 ± 0.9 | 3.9 ± 0.4 | 4.8 ± 0.9 | 3.6 ± 0.3 | [B>T-,P-; T+>P-; P+>all]
PMID 15975147 · one of two readings recorded this
DHA concentration, Optic Tract
modulates
Optic Tract | 4.8 ± 0.5 | 4.5 ± 0.4 | 4.3 ± 0.6 | 5.1 ± 0.3 | 3.9 ± 0.4 | [B,T+>P-; P+>T+,T-,P-]
PMID 15975147 · one of two readings recorded this
DHA concentration, Post-Centralis
modulates
Post-Centralis | 14.1 ± 0.8 | 12.7 ± 0.8 | 11.7 ± 1.0 | 13.4 ± 0.6 | 10.4 ± 0.2 | [B>T+,T-,P-; T+>T-,P-; P+>T-,P-; T->P-]
PMID 15975147 · one of two readings recorded this
DHA concentration, Pre-Centralis
modulates
Pre-Centralis | 14.4 ± 0.9 | 12.6 ± 0.6 | 11.7 ± 1.0 | 13.0 ± 0.6 | 10.4 ± 0.7 | [B>all; T+>P-; P+>T-,P-; T->P-]
PMID 15975147 · one of two readings recorded this
DHA concentration, Pulvinar
modulates
Pulvinar | 13.5 ± 0.6 | 12.7 ± 0.7 | 12.5 ± 1.0 | 14.6 ± 1.1 | 12.0 ± 0.4 | [B>T-,P-; P+>all]
PMID 15975147 · one of two readings recorded this
DHA concentration, Putamen
modulates
Putamen | 14.7 ± 0.8 | 13.9 ± 0.9 | 13.5 ± 0.6 | 13.6 ± 1.3 | 11.6 ± 0.8 | [B>T-,P-; T+,T-,P+>P-]
PMID 15975147 · one of two readings recorded this
DHA concentration, Spinal Cord
no effect
Spinal Cord1 | 5.7 ± 0.3 | 6.0 ± 1.0 | 5.6 ± 0.5 | 6.2 ± 0.5 | 5.1 ± 0.6
PMID 15975147 · one of two readings recorded this
DHA concentration, Superior Colliculus
modulates
Superior Colliculus | 15.2 ± 1.2 | 14.2 ± 1.1 | 13.6 ± 0.5 | 15.0 ± 0.4 | 13.4 ± 0.7 | [B>T-,P-; P+>T-,P-]
PMID 15975147 · one of two readings recorded this
DHA concentration, Temporal
modulates
Temporal | 12.2 ± 0.6 | 10.5 ± 1.1 | 10.3 ± 0.8 | 11.2 ± 0.5 | 9.0 ± 0.7 | [B>all; T+,T-,P+>P-]
PMID 15975147 · one of two readings recorded this
DHA concentration, Thalamus DM
modulates
Thalamus DM | 13.0 ± 1.0 | 12.4 ± 1.2 | 12.2 ± 0.9 | 13.5 ± 0.8 | 10.9 ± 1.3 | [B>P-; T+,T-,P+>P-]
PMID 15975147 · one of two readings recorded this
DHA concentration, Thalamus VPL
modulates
Thalamus VPL | 12.9 ± 0.7 | 12.6 ± 0.9 | 12.2 ± 0.9 | 13.1 ± 1.7 | 10.3 ± 1.6 | [B>P-; T+,T-,P+>P-]
PMID 15975147 · one of two readings recorded this
effect of supplementation on CNS ARA concentrations
no effect
The trends for ARA are very different from those for DHA. As noted, treatments were ineffective at altering ARA concentrations in 18 regions
PMID 15975147 · one of two readings recorded this
highest regional CNS ARA concentration (amygdala)
ARA concentrations range from a high of 13.7 ± 0.5% in the amygdala to a low of 6.8 ± 0.4% in the optic tract
PMID 15975147 · one of two readings recorded this
highest regional CNS DHA concentration (globus pallidus)
The globus pallidus has the highest DHA concentration at 15.8 ± 0.5% (w/w), while the optic nerve is lowest at 4.5 ± 0.4%
PMID 15975147 · one of two readings recorded this
lowest regional CNS ARA concentration (optic tract)
ARA concentrations range from a high of 13.7 ± 0.5% in the amygdala to a low of 6.8 ± 0.4% in the optic tract
PMID 15975147 · one of two readings recorded this
lowest regional CNS DHA concentration (optic nerve)
The globus pallidus has the highest DHA concentration at 15.8 ± 0.5% (w/w), while the optic nerve is lowest at 4.5 ± 0.4%
PMID 15975147 · one of two readings recorded this
Osbond acid (22:5n-6) elevation without dietary DHA
increases
In 25 of 26 CNS regions (except thalamus DM), P- was significantly elevated, while T- was significantly elevated in 22 of 26 regions
PMID 15975147 · one of two readings recorded this
stearic acid and adrenic acid (22:4n-6) variation with treatment
no effect
Neither 18:0 (stearic acid) nor 22:4n-6 (adrenic acid) showed any statistically significant variation as a function of treatment in these regions
PMID 15975147 · one of two readings recorded this
epididymosomal membrane rigidity (anisotropy)
increases
Measures of epididymosomal membrane anisotropy revealed that epididymosomes became more rigid during epididymal transit
PMID 16510839 · one of two readings recorded this
epididymosome cholesterol:phospholipid ratio
increases
The cholesterol:phospholipid ratio increased from 0.26 in the caput to 0.48 in the cauda epididymidis
PMID 16510839 · one of two readings recorded this
epididymosome cholesterol:phospholipid ratio
increases
The cholesterol:phospholipid ratio increased from 0.26 in the caput to 0.48 in the cauda epididymidis
PMID 16510839 · one of two readings recorded this
epididymosome sphingomyelin and arachidonic acid content
found that epididymosomes were particularly rich in sphingomyelin (SM) and arachidonic acid
PMID 16510839 · one of two readings recorded this
epididymosome sphingomyelin proportion during epididymal transit
increases
The proportion of SM increased markedly during epididymal transit and represented half the total phospholipids in cauda epididymidal epididymosomes
PMID 16510839 · one of two readings recorded this
spermatozoal cholesterol:phospholipid ratio
no effect
Epididymal spermatozoa had a constant cholesterol:phospholipid ratio (average, 0.30) during epididymal transit
PMID 16510839 · one of two readings recorded this
spermatozoal sphingomyelin and polyunsaturated fatty acids (arachidonic, docosapentanoic, docosahexanoic acids)
increases
Both SM and PUFA increased throughout the epididymal tract
PMID 16510839 · one of two readings recorded this
syntaxin 3 activation by dietary omega-3 linolenic and docosahexaenoic acids relative to arachidonic acid
increases
By using syntaxin 3 in a screening assay, we determined that the dietary omega-3 linolenic and docosahexaenoic acids can efficiently substitute for arachidonic acid in activating syntaxin 3
PMID 16598260 · one of two readings recorded this
syntaxin 3 activation
increases
Here we show that syntaxin 3 (STX3), a plasma membrane protein, has an important role in the growth of neurites, and also serves as a direct target for omega-6 arachidonic acid
PMID 16598260 · one of two readings recorded this
15d-PGJ2 formation
increases
Stimulation by LPS of selenium-supplemented macrophages resulted in a time-dependent increase in 15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) formation, an endogenous inhibitor of IKKbeta activity.
PMID 17439952 · one of two readings recorded this
15d-PGJ2 synthesis dependence on COX-1 versus COX-2
increases
Experiments using specific cyclooxygenase (COX) inhibitors and genetic knockdown approaches indicated that COX-1, and not the COX-2 pathway, was responsible for the increased synthesis of 15d-PGJ2 in selenium-supplemented macrophages.
PMID 17439952 · one of two readings recorded this
IKKbeta activity
decreases
In vitro kinase assays revealed that selenium supplementation decreased the activity of IKKbeta in lipopolysaccharide (LPS)-treated macrophages.
PMID 17439952 · one of two readings recorded this
association of erythrocyte ARA with adipose ARA
increases, p = 0.001
erythrocyte ARA correlated with adipose ARA (r(2) = 0.470; P < 0.001)
PMID 17709441 · one of two readings recorded this
association of plasma and erythrocyte ARA with neural ARA
no effect
Plasma and erythrocyte ARA did not correlate with neural ARA
PMID 17709441 · one of two readings recorded this
association of plasma and erythrocyte DHA with neural and visceral tissue DHA
increases, p = 0.001
Plasma and erythrocyte DHA were positively associated with DHA in neural (brain and retina) and visceral (liver and adipose) tissues (r(2) = 0.11-0.56; P < 0.001-P = 0.042)
PMID 17709441 · one of two readings recorded this
association of plasma ARA with adipose ARA
increases, p = 0.001
adipose ARA (r(2) = 0.867; P < 0.001)
PMID 17709441 · one of two readings recorded this
association of plasma ARA with liver ARA
increases, p = 0.02
Only plasma ARA was associated with liver ARA (r(2) = 0.222; P = 0.02)
PMID 17709441 · one of two readings recorded this
brain and retina ARA
no effect
brain and retina ARA was, however, unresponsive to dietary DHA and ARA
PMID 17709441 · one of two readings recorded this
tissue ARA in liver, adipose tissue, plasma, erythrocytes
increases, p = 0.05
Tissue ARA (1.1- to 6.0-fold of Diet 0) responded to dietary ARA in liver, adipose tissue, plasma, and erythrocytes (P-trend < 0.05)
PMID 17709441 · one of two readings recorded this
tissue DHA (brain, retina, liver, adipose tissue, plasma, erythrocyte)
increases, p = 0.01
Supplementation of dietary DHA and ARA increased DHA in brain, retina, liver, adipose tissue, plasma, and erythrocyte by 1.1- to 25.8-fold of Diet 0 (P-trend < 0.01)
PMID 17709441 · one of two readings recorded this
brain 20:5omega-3 and 22:5omega-3
no effect
DHA supplementation effectively increased DHA, but not the intermediate omega-3 fatty acids, 20:5omega-3 and 22:5omega-3
PMID 18710653 · one of two readings recorded this
brain 22:4omega-6 and 22:5omega-6
increases
a contemporary diet, high in 18:2omega-6 compromises DHA accretion and leads to increased 22:4omega-6 and 22:5omega-6 in the brain
PMID 18710653 · one of two readings recorded this
brain DHA accretion
decreases
a contemporary diet, high in 18:2omega-6 compromises DHA accretion and leads to increased 22:4omega-6 and 22:5omega-6 in the brain
PMID 18710653 · one of two readings recorded this
brain DHA
increases
DHA supplementation effectively increased DHA, but not the intermediate omega-3 fatty acids, 20:5omega-3 and 22:5omega-3
PMID 18710653 · one of two readings recorded this
brain DHA
increases
an evolutionary diet, low in 18:2omega-6, supports high brain DHA
PMID 18710653 · one of two readings recorded this
neuronal uptake and acylation
increases
Using primary cultures of cortical neurons, we show that 22:5omega-6 is efficiently acylated and preferentially taken up over DHA
PMID 18710653 · one of two readings recorded this
secondary neurite growth
no effect
However, DHA, but not 22:5omega-6 supports growth of secondary neurites
PMID 18710653 · one of two readings recorded this
secondary neurite growth
increases
However, DHA, but not 22:5omega-6 supports growth of secondary neurites
PMID 18710653 · one of two readings recorded this
connexin 40 (gap junction 40) gene expression in aorta
increases, p = 0.05
Significant and marked differences were detected for the endothelial nitric oxide synthase (eNOS) gene (1.89-fold, P<0.05) and the connexin 40 (gap junction 40) gene (2.81-fold, P<0.05)
PMID 19686729 · one of two readings recorded this
cyclooxygenase (COX-1) gene expression in aorta
increases
Administration of VPP and IPP led to a slight increase in the expression of the cyclooxigenase (COX-1) gene
PMID 19686729 · one of two readings recorded this
endothelial nitric oxide synthase (eNOS) gene expression in aorta
increases, p = 0.05
Significant and marked differences were detected for the endothelial nitric oxide synthase (eNOS) gene (1.89-fold, P<0.05) and the connexin 40 (gap junction 40) gene (2.81-fold, P<0.05)
PMID 19686729 · one of two readings recorded this
NF-kappaB subunit gene expression in aorta
decreases
a decrease in the expression of both the nuclear factor kappa B subunit (NF-kappaB) gene for vascular function and the peroxisome proliferator activator receptor gamma (PPARgamma) gene
PMID 19686729 · one of two readings recorded this
PPARgamma gene expression in aorta
decreases
a decrease in the expression of both the nuclear factor kappa B subunit (NF-kappaB) gene for vascular function and the peroxisome proliferator activator receptor gamma (PPARgamma) gene
PMID 19686729 · one of two readings recorded this
breeding success rate of DHA-supplemented (-/-) males
no effect
A breeding success rate of DHA-supplemented (-/-) was comparable to (+/+)
PMID 19690334 · one of two readings recorded this
fertility, sperm count and spermiogenesis of delta-6 desaturase-null males, dietary AA compared with dietary DHA
Not recorded as a finding: comparator is DHA, an active comparator, not an unsupplemented control; the sentence gives no AA-versus-unsupplemented contrast, and sperm count is reported without a number
Dietary AA was less effective in restoring fertility, sperm count, and spermiogenesis than DHA.
PMID 19690334 · one of two readings recorded this
fertility, sperm count and spermiogenesis with dietary AA versus DHA
increases
Dietary AA was less effective in restoring fertility, sperm count, and spermiogenesis than DHA
PMID 19690334 · one of two readings recorded this
male fertility (breeding success rate), sperm count and spermiogenesis in delta-6 desaturase-null mice fed 0.2% (w/w) AA or DHA diet
Not recorded as a finding: the comparison was against another active treatment
Dietary AA was less effective in restoring fertility, sperm count, and spermiogenesis than DHA.
PMID 19690334 · one of two readings recorded this
testis AA level in AA-fed (-/-)
increases
In AA-fed (-/-), AA was restored at the (+/+) level, and 22:4n6, an AA elongated product, accumulated in testis
PMID 19690334 · one of two readings recorded this
testis cholesta-3,5-diene
decreases
Cholesta-3,5-diene was present in testis of (+/+) and DHA-fed (-/-), whereas it diminished in (-/-) and AA-fed (-/-)
PMID 19690334 · one of two readings recorded this
glucose infusion rate during clamp
decreases, p = 0.05
Glucose infusion rates in Wistar rats maintained on a high fat diet (HFD) were significantly lower compared to control rats (22.8 ± 1.3 vs. 31.9 ± 1.4 mg/kg/min; p<0.05)
PMID 21167181 · one of two readings recorded this
glucose infusion rate during clamp
increases, p = 0.05
ZA treatment significantly improved (~43%) peripheral tissue insulin sensitivity in HFD fed animals (26.7 ± 1.3 [n=9] vs. 22.8 ± 1.3mg/kg/min; p<0.05)
PMID 21167181 · one of two readings recorded this
hepatic glucose output during clamp
decreases, p = 0.05
ZA treatment in high fructose-fed rats showed a significant improvement of hepatic insulin sensitivity compared to non-treatment controls (4.39 vs. 2.18 mg/kg/min; p<0.05)
PMID 21167181 · one of two readings recorded this
hepatic glucose output suppression and glucose infusion rate, hyperinsulinemic euglycemic clamp
increases, glucose infusion rate 26.7 vs 22.8 mg/kg/min in high-fat-fed rats
Not recorded as a finding: the intervention held more than the compound
ZA treatment significantly improved (~43%) peripheral tissue insulin sensitivity in HFD fed animals (26.7 ± 1.3 [n=9] vs. 22.8 ± 1.3mg/kg/min; p<0.05).
PMID 21167181 · one of two readings recorded this
insulin sensitivity by hyperinsulinemic euglycemic clamp (hepatic glucose output suppression; glucose infusion rate)
increases, ~43% improvement in peripheral tissue insulin sensitivity in HFD-fed rats (26.7 vs 22.8 mg/kg/min)
Not recorded as a finding: the intervention held more than the compound
ZA treatment significantly improved (~43%) peripheral tissue insulin sensitivity in HFD fed animals (26.7 ± 1.3 [n=9] vs. 22.8 ± 1.3mg/kg/min; p<0.05).
PMID 21167181 · one of two readings recorded this
suppression of hepatic glucose output by insulin during clamp
increases, p = 0.05
High fructose feeding impaired suppression of hepatic glucose output by insulin compared to controls during the clamp procedure (4.39 vs. 2.35 mg/kg/min; p<0.05)
PMID 21167181 · one of two readings recorded this
action potential amplitude, 3xTg-AD versus NonTg
decreases, p = 0.01
we observed a decrease in the amplitude of action potentials (P<0.01, Figure 4D), an increase of undershoot voltage variation (P<0.001, Figure 4E) and a reduction of post-spike hyperpolarization (P<0.05, Figure 4F) in 3xTg-AD neurons
PMID 21383850 · one of two readings recorded this
action potential undershoot voltage variation, 3xTg-AD versus NonTg
increases, p = 0.001
we observed a decrease in the amplitude of action potentials (P<0.01, Figure 4D), an increase of undershoot voltage variation (P<0.001, Figure 4E) and a reduction of post-spike hyperpolarization (P<0.05, Figure 4F) in 3xTg-AD neurons
PMID 21383850 · one of two readings recorded this
adaptativity ratio, 3xTg-AD
no effect
0.27±0.05 (n = 7) for 3xTg-AD mice fed with control diet and 0.22±0.05 (n = 8) for NonTg mice fed with high-DHA diet
PMID 21383850 · one of two readings recorded this
adaptativity ratio, NonTg
no effect
was 0.33±0.05 (n = 8) for NonTg mice fed with control diet, 0.35±0.03 (n = 7) for NonTg mice fed with high-DHA diet
PMID 21383850 · one of two readings recorded this
akinetic (low and very low activity) episodes in 3xTg-AD mice
decreases, p = 0.05
DHA intake reduced the number of akinetic episodes seen in 3xTg-AD mice (P<0.05, low and very low activity episodes, Figure 2I–J)
PMID 21383850 · one of two readings recorded this
amyloid-beta pathology in cortex
no effect
We found no significant effects of DHA on Aβ pathologies
PMID 21383850 · one of two readings recorded this
body weight, 3xTg-AD versus NonTg
increases, p = 0.001
As reported previously, 3xTg-AD mice were heavier than NonTg mice (31% for mice fed with control diet and 16% for mice fed with high-DHA diet, P<0.001)
PMID 21383850 · one of two readings recorded this
correlation between cortical AA and DHA concentrations
decreases, p = 0.001
we found an inverse relationship between AA and DHA concentrations (r2 = 0.61, P<0.001, data not shown)
PMID 21383850 · one of two readings recorded this
entorhinal neuron cell capacitance, 3xTg-AD versus NonTg
decreases, p = 0.05
CC, an indicator of total membrane area, was decreased in neurons from 3xTg-AD mice compared to NonTg (P<0.05; Figure 3A, 3B)
PMID 21383850 · one of two readings recorded this
entorhinal neuron cell capacitance with DHA
increases, p = 0.05
DHA treatment prevented this decrease and had an overall increasing effect on CC in all animals (P<0.05)
PMID 21383850 · one of two readings recorded this
F-I curve, 3xTg-AD versus NonTg
increases, p = 0.001
we found that the F-I curves were increased in 3xTg-AD mice (P<0.001), but decreased by DHA treatment (P<0.01, Figure 5A–C)
PMID 21383850 · one of two readings recorded this
F-I curve with DHA
decreases, p = 0.01
we found that the F-I curves were increased in 3xTg-AD mice (P<0.001), but decreased by DHA treatment (P<0.01, Figure 5A–C)
PMID 21383850 · one of two readings recorded this
first-exposure object exploration time, 3xTg-AD
no effect
whereas it was 72±6 (n = 7) and 72±5 (n = 8) for 3xTg-AD mice fed with control or high-DHA diet
PMID 21383850 · one of two readings recorded this
first-exposure object exploration time, NonTg
increases
The time spent in seconds to explore the object during the first exposition was 88±3 (n = 8) and 114±3 (n = 8) for NonTg mice fed with control or high-DHA diet
PMID 21383850 · one of two readings recorded this
frontal cortex arachidonic acid (AA) level
decreases, p = 0.001
mice fed a high-DHA diet had lower brain levels of AA (−22% for NonTg mice and −25% for 3xTg-AD; P<0.001, Figure 1B)
PMID 21383850 · one of two readings recorded this
frontal cortex arachidonic acid (AA) level
decreases, p = 0.001
mice fed a high-DHA diet had lower brain levels of AA (−22% for NonTg mice and −25% for 3xTg-AD; P<0.001, Figure 1B)
PMID 21383850 · one of two readings recorded this
frontal cortex arachidonic acid concentration, gas chromatography, in mice fed a high-DHA diet versus control diet
decreases, -22% in NonTg mice and -25% in 3xTg-AD mice
Not recorded as a finding: the compound is what was measured, not what was given
In parallel, mice fed a high-DHA diet had lower brain levels of AA (−22% for NonTg mice and −25% for 3xTg-AD; P<0.001, Figure 1B) and, therefore, a lower DHA/AA ratio (44% for NonTg and 68% for 3xTg-AD, P<0.001, Table S1).
PMID 21383850 · one of two readings recorded this
frontal cortex DHA/AA ratio
increases, p = 0.001
and, therefore, a lower DHA/AA ratio (44% for NonTg and 68% for 3xTg-AD, P<0.001, Table S1)
PMID 21383850 · one of two readings recorded this
frontal cortex DHA/AA ratio
increases, p = 0.001
and, therefore, a lower DHA/AA ratio (44% for NonTg and 68% for 3xTg-AD, P<0.001, Table S1)
PMID 21383850 · one of two readings recorded this
frontal cortex DHA level
increases, p = 0.001
high DHA consumption induced an increase in frontal cortex DHA of 15% in NonTg mice and of 27% in 3xTg-AD mice, compared to mice fed control diet (P<0.001, Figure 1A and Table S1)
PMID 21383850 · one of two readings recorded this
frontal cortex DHA level
increases, p = 0.001
high DHA consumption induced an increase in frontal cortex DHA of 15% in NonTg mice and of 27% in 3xTg-AD mice, compared to mice fed control diet (P<0.001, Figure 1A and Table S1)
PMID 21383850 · one of two readings recorded this
horizontal locomotor activity, 3xTg-AD versus NonTg
decreases, p = 0.001
We observed diminished horizontal (P<0.001) and vertical activities (P<0.001) in 3xTg-AD compared to NonTg mice
PMID 21383850 · one of two readings recorded this
hyperpolarization of entorhinal neurons by DHA, NonTg
decreases, p = 0.001
DHA consumption led to the hyperpolarization of EC neurons of NonTg mice (P<0.001, Figure 3G)
PMID 21383850 · one of two readings recorded this
novel-object recognition, 3xTg-AD versus NonTg
decreases, p = 0.05
3xTg-AD performed significantly worse than NonTg mice (P<0.05)
PMID 21383850 · one of two readings recorded this
novel-object recognition with DHA
increases, p = 0.05
the consumption of DHA improved the recognition performance of both NonTg and 3xTg-AD mice (P<0.05)
PMID 21383850 · one of two readings recorded this
post-spike hyperpolarization, 3xTg-AD versus NonTg
decreases, p = 0.05
we observed a decrease in the amplitude of action potentials (P<0.01, Figure 4D), an increase of undershoot voltage variation (P<0.001, Figure 4E) and a reduction of post-spike hyperpolarization (P<0.05, Figure 4F) in 3xTg-AD neurons
PMID 21383850 · one of two readings recorded this
resting potential, CC, input resistance and F-I curves after acute DHA
no effect
We found that acute application of DHA did not alter the resting potential, CC, input resistance or F-I curves
PMID 21383850 · one of two readings recorded this
resting potential of entorhinal neurons with DHA, NonTg
decreases
DHA intake hyperpolarized EC neurons by altering their resting potential from −60 mV to −70 mV, an effect only present in NonTg mice
PMID 21383850 · one of two readings recorded this
rheobase with DHA, NonTg
increases, p = 0.01
an increase of rheobase was detected in DHA-enriched neurons from NonTg mice (P<0.01, Figure 5D)
PMID 21383850 · one of two readings recorded this
sEPSC frequency, 3xTg-AD versus NonTg
increases, p = 0.001
3xTg-AD neurons displayed more sEPSC than NonTg (<0.001)
PMID 21383850 · one of two readings recorded this
sEPSC frequency with DHA
increases, p = 0.01
DHA treatment did not prevent synaptic hyperactivity of EC neurons, but rather increased the frequency of sEPSC in all animals (<0.01)
PMID 21383850 · one of two readings recorded this
soluble phosphorylated tau in cortex
decreases, p = 0.05
DHA intake selectively decreased phosphorylated tau (ptau) in TBS fractions (P<0.05, Figure 1D-F, Table S2)
PMID 21383850 · one of two readings recorded this
synaptophysin and PSD95 with DHA
no effect
DHA intake had no effect on both pre- and postsynaptic markers
PMID 21383850 · one of two readings recorded this
vertical locomotor activity, 3xTg-AD versus NonTg
decreases, p = 0.001
We observed diminished horizontal (P<0.001) and vertical activities (P<0.001) in 3xTg-AD compared to NonTg mice
PMID 21383850 · one of two readings recorded this
hip fracture risk and intakes of EPA, DHA, EPA+DHA and fish
no effect
No significant associations were observed among intakes of EPA, DHA, EPA+DHA, or fish
PMID 21508210 · one of two readings recorded this
hip fracture risk, Q4 vs Q1 of AA intake
decreases
Men in the highest quartile of AA intake had an 80% lower risk of hip fracture than those in the lowest quartile (Q4 vs. Q1: HR = 0.20; 95% CI = 0.04-0.96)
PMID 21508210 · one of two readings recorded this
hip fracture risk, Q4 vs Q1 of ALA intake
decreases
Participants in the highest quartile of ALA intake had a 54% lower risk of hip fracture than those in the lowest quartile (Q4 vs. Q1: HR = 0.46; 95% CI = 0.26-0.83)
PMID 21508210 · one of two readings recorded this
hip fracture risk, trend across quartiles of AA intake
decreases, p = 0.05
Protective associations were observed between intakes of ALA (P-trend = 0.02) and hip fracture risk in a combined sample of women and men and between intakes of AA (P-trend = 0.05) and hip fracture risk in men only
PMID 21508210 · one of two readings recorded this
hip fracture risk, trend across quartiles of ALA intake
decreases, p = 0.02
Protective associations were observed between intakes of ALA (P-trend = 0.02) and hip fracture risk in a combined sample of women and men and between intakes of AA (P-trend = 0.05) and hip fracture risk in men only
PMID 21508210 · one of two readings recorded this
incident hip fracture by quartile of energy-adjusted dietary arachidonic acid intake, Framingham Osteoporosis Study; arachidonic acid association found in men only. Reason is that the exposure is habitual dietary intake nobody was given, not a supplement, enriched oil or formula
decreases, Q4 vs Q1 HR 0.20 (95% CI 0.04-0.96), men only
Not recorded as a finding: another reason, stated per paper
Men in the highest quartile of AA intake had an 80% lower risk of hip fracture than those in the lowest quartile (Q4 vs. Q1: HR = 0.20; 95% CI = 0.04-0.96).
PMID 21508210 · one of two readings recorded this
chronic lung disease (CLD) odds per 1 mol% reduction in DHA
increases
For every 1 mol% reduction in whole blood DHA levels, there was a 2.5-fold increase in the odds of developing CLD (CI 1.3 – 5.0)
PMID 21658712 · one of two readings recorded this
CLD association with AA level
no effect
LA and AA birth and follow-up levels were not associated with the development of CLD
PMID 21658712 · one of two readings recorded this
CLD association with DHA, significance after adjustment
increases, p = 0.001
remained significant even after adjustment for gestational age, intrauterine growth restriction, severity of illness at birth, sex, and total fat intake during the first postnatal week (p=0.001)
PMID 21658712 · one of two readings recorded this
CLD association with LA:DHA, AA:DHA and n-6:n-3 ratios
increases
Increased LA:DHA, AA:DHA and n-6:n-3 ratios were associated with CLD although the large confidence intervals for the latter two limit their interpretability
PMID 21658712 · one of two readings recorded this
CLD association with LA level
no effect
LA and AA birth and follow-up levels were not associated with the development of CLD
PMID 21658712 · one of two readings recorded this
CLD prevalence
ROP was present in 45% of the cohort, CLD 48%, sepsis (early or late) 20%, intraventricular hemorrhage 35%, periventricular leukomalacia 3%, and necrotizing enterocolitis 6%
PMID 21658712 · one of two readings recorded this
DHA level in early-onset sepsis
no effect, n = 2
No differences were observed in mean DHA levels at birth or during the follow-up period in infants who developed early-onset sepsis (n=2), intraventricular hemorrhage (n=31), periventricular leukomalacia (n=3), or NEC (n=5)
PMID 21658712 · one of two readings recorded this
DHA level in intraventricular hemorrhage
no effect, n = 31
No differences were observed in mean DHA levels at birth or during the follow-up period in infants who developed early-onset sepsis (n=2), intraventricular hemorrhage (n=31), periventricular leukomalacia (n=3), or NEC (n=5)
PMID 21658712 · one of two readings recorded this
DHA level in necrotizing enterocolitis
no effect, n = 5
No differences were observed in mean DHA levels at birth or during the follow-up period in infants who developed early-onset sepsis (n=2), intraventricular hemorrhage (n=31), periventricular leukomalacia (n=3), or NEC (n=5)
PMID 21658712 · one of two readings recorded this
DHA level in periventricular leukomalacia
no effect, n = 3
No differences were observed in mean DHA levels at birth or during the follow-up period in infants who developed early-onset sepsis (n=2), intraventricular hemorrhage (n=31), periventricular leukomalacia (n=3), or NEC (n=5)
PMID 21658712 · one of two readings recorded this
intraventricular hemorrhage prevalence
ROP was present in 45% of the cohort, CLD 48%, sepsis (early or late) 20%, intraventricular hemorrhage 35%, periventricular leukomalacia 3%, and necrotizing enterocolitis 6%
PMID 21658712 · one of two readings recorded this
late-onset sepsis association with LA:DHA ratio
increases, p = 0.007
An increased LA:DHA ratio was associated with late-onset sepsis (p=0.007)
PMID 21658712 · one of two readings recorded this
late-onset sepsis hazard per unit decrease in DHA
unclear
For every unit decrease in DHA mol% at a given time, there was a 1.4-fold increase in the risk of late-onset sepsis (CI 1.0 – 2.0), though this did not meet statistical significance
PMID 21658712 · one of two readings recorded this
late-onset sepsis hazard with higher LA level
increases, p = 0.02
lower AA levels and higher LA levels were significantly associated with the development of late-onset sepsis with a hazard ratio of 1.4 (CI 1.1 – 1.7; p=0.02) and 1.3 (CI 1.04 – 1.4; p=0.02), respectively
PMID 21658712 · one of two readings recorded this
late-onset sepsis hazard with lower AA level
increases, p = 0.02
lower AA levels and higher LA levels were significantly associated with the development of late-onset sepsis with a hazard ratio of 1.4 (CI 1.1 – 1.7; p=0.02) and 1.3 (CI 1.04 – 1.4; p=0.02), respectively
PMID 21658712 · one of two readings recorded this
late-onset sepsis incidence
n = 88
Late-onset sepsis occurred in 16 of 88 (18%) infants
PMID 21658712 · one of two readings recorded this
mortality
The mortality rate for the entire cohort was 11% (Table I)
PMID 21658712 · one of two readings recorded this
necrotizing enterocolitis prevalence
ROP was present in 45% of the cohort, CLD 48%, sepsis (early or late) 20%, intraventricular hemorrhage 35%, periventricular leukomalacia 3%, and necrotizing enterocolitis 6%
PMID 21658712 · one of two readings recorded this
periventricular leukomalacia prevalence
ROP was present in 45% of the cohort, CLD 48%, sepsis (early or late) 20%, intraventricular hemorrhage 35%, periventricular leukomalacia 3%, and necrotizing enterocolitis 6%
PMID 21658712 · one of two readings recorded this
retinopathy of prematurity (ROP) association with DHA level
no effect
no significant association between DHA levels nor in AA and LA levels in the follow-up period were associated with the development of ROP
PMID 21658712 · one of two readings recorded this
ROP association with AA level
no effect
no significant association between DHA levels nor in AA and LA levels in the follow-up period were associated with the development of ROP
PMID 21658712 · one of two readings recorded this
ROP association with LA:DHA, AA:DHA and n-6:n-3 ratios
no effect
none of the three ratios was associated with ROP
PMID 21658712 · one of two readings recorded this
ROP association with LA level
no effect
no significant association between DHA levels nor in AA and LA levels in the follow-up period were associated with the development of ROP
PMID 21658712 · one of two readings recorded this
ROP prevalence
ROP was present in 45% of the cohort, CLD 48%, sepsis (early or late) 20%, intraventricular hemorrhage 35%, periventricular leukomalacia 3%, and necrotizing enterocolitis 6%
PMID 21658712 · one of two readings recorded this
sepsis (early or late) prevalence
ROP was present in 45% of the cohort, CLD 48%, sepsis (early or late) 20%, intraventricular hemorrhage 35%, periventricular leukomalacia 3%, and necrotizing enterocolitis 6%
PMID 21658712 · one of two readings recorded this
whole blood 22:5n-3 fold change from birth
increases
In the n-3 pathway, there was an increase in 20:5n-3 (EPA) and 22:5n-3 compared with birth levels, 1.7 and 1.5-fold respectively; but a decrease in the downstream product, 22:6n-3 (DHA) by 1.6-fold
PMID 21658712 · one of two readings recorded this
whole blood AA level
At birth, the mean mol% ± SE (standard error) for LA was 7.0 ± 0.2, 17.2 ± 0.2 for AA, and 6.9 ± 0.2 for DHA
PMID 21658712 · one of two readings recorded this
whole blood AA level
decreases
AA levels declined by 30% from 17.2 mol% at birth to 11.8 mol% at week 1 and remained constant at 11.4 to 11.6 mol% for the remaining three postnatal weeks
PMID 21658712 · one of two readings recorded this
whole blood ALA (18:3n-3) fold change from birth
increases
by 19.2 and 1.1-fold, respectively
PMID 21658712 · one of two readings recorded this
whole blood DHA (22:6n-3) fold change from birth
decreases
In the n-3 pathway, there was an increase in 20:5n-3 (EPA) and 22:5n-3 compared with birth levels, 1.7 and 1.5-fold respectively; but a decrease in the downstream product, 22:6n-3 (DHA) by 1.6-fold
PMID 21658712 · one of two readings recorded this
whole blood DHA level
At birth, the mean mol% ± SE (standard error) for LA was 7.0 ± 0.2, 17.2 ± 0.2 for AA, and 6.9 ± 0.2 for DHA
PMID 21658712 · one of two readings recorded this
whole blood DHA level
decreases
The mean DHA level fell by approximately 40% from 6.9 mol% at birth to 4.4 mol% at week 1, and subsequently remained steady at 4.0 to 4.2 mol% for the remainder of the postnatal period
PMID 21658712 · one of two readings recorded this
whole blood EPA (20:5n-3) fold change from birth
increases
In the n-3 pathway, there was an increase in 20:5n-3 (EPA) and 22:5n-3 compared with birth levels, 1.7 and 1.5-fold respectively; but a decrease in the downstream product, 22:6n-3 (DHA) by 1.6-fold
PMID 21658712 · one of two readings recorded this
whole blood LA (18:2n-6) fold change from birth
increases
In addition to a 2.7-fold increase in the essential fatty acid 18:2n-6 (LA)
PMID 21658712 · one of two readings recorded this
whole blood LA level
At birth, the mean mol% ± SE (standard error) for LA was 7.0 ± 0.2, 17.2 ± 0.2 for AA, and 6.9 ± 0.2 for DHA
PMID 21658712 · one of two readings recorded this
whole blood LA level
increases
The mean LA level increased from 7.0 mol% at birth to 18.8 mol% at week 1 and remained level over the subsequent 4 weeks
PMID 21658712 · one of two readings recorded this
whole blood oleic acid (18:1n-9) fold change from birth
increases
by 19.2 and 1.1-fold, respectively
PMID 21658712 · one of two readings recorded this
16:1 and 18:1 CE molecular species
increases
In particular, the Western diet led to large increases in both 16:1 and 18:1 CE molecular species
PMID 21904795 · one of two readings recorded this
18:1 CE
decreases
With both fatty acid supplementations to the cell culture media the respective CE molecular species increased with an accompanied decrease in the amount of 18:1 CE
PMID 21904795 · one of two readings recorded this
18:2 CE
increases
Figure 4, Panel B demonstrates that J774 cells supplemented with linoleic acid in the media have increased levels of intracellular 18:2 CE (m/z 671.73)
PMID 21904795 · one of two readings recorded this
22:4 and 24:4 CE molecular species (elongation of 20:4)
increases
Studies with arachidonic acid supplementation of J774 cells unexpectedly revealed that arachidonic acid addition led to an increase in elongated CE molecular species, which were observed in the CE pool
PMID 21904795 · one of two readings recorded this
air oxidation of 18:0 CE
no effect
NL 368.5 scans of 18:0 CE exposed to ambient air for 15 h indicated that this saturated molecular species was not degraded in an oxidizing environment
PMID 21904795 · one of two readings recorded this
air oxidation of polyunsaturated CE (18:2, 20:4, 22:6)
increases
In contrast, 18:2, 20:4 and 22:6 CE molecular species were significantly oxidized after exposure to ambient air for 15 h
PMID 21904795 · one of two readings recorded this
arachidonic acid incorporation into CE pool (20:4 CE)
increases
Interestingly, as shown in Figure 4 (Panel C), J774 cells incorporate arachidonic acid into CE pools (m/z 695.72)
PMID 21904795 · one of two readings recorded this
basal CE composition (18:1 CE predominant)
unclear
The mass spectra using NL 368.5 for cells without fatty acid treatment revealed that 18:1 CE (m/z 673.73) was predominantly present in J774 cells grown in the cell culture media with minimal levels of 18:2 and 20:4 CE present in these cells
PMID 21904795 · one of two readings recorded this
total CE
no effect
The total CE levels only marginally changed in cells treated with fatty acids due to the accumulation of new molecular species being offset by the decrease in 18:1 CE levels
PMID 21904795 · one of two readings recorded this